ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Columbus, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Columbus, OH, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Columbus, Ohio, United States and 72 other locations

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Columbus, Ohio, United States and 124 other locations

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC).The study will compris...

Enrolling
Non-Small Cell Lung Cancer
Biological: BNT116
Biological: Bispecific antibody for PD-L1 and VEGF-A

Phase 1

BioNTech
BioNTech

Columbus, Ohio, United States and 46 other locations

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy ...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 3

AstraZeneca
AstraZeneca

Columbus, Ohio, United States and 246 other locations

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NAUTIKA1)

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and...

Enrolling
Non-small Cell Lung Cancer
Drug: Divarasib
Procedure: Resection

Phase 2

Genentech
Genentech

Columbus, Ohio, United States and 37 other locations

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Ca...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: platinum-based chemotherapy
Drug: furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Columbus, Ohio, United States and 207 other locations

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02)

or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung ...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Sacituzumab Govitecan-hziy (SG)
Drug: Pembrolizumab

Phase 2

Gilead Sciences
Gilead Sciences

Columbus, Ohio, United States and 100 other locations

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) w...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: S095024 RDE
Drug: S095029 RDE

Phase 1, Phase 2

Servier
Servier

Columbus, Ohio, United States and 57 other locations

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)

of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung ca...

Enrolling
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Pemetrexed

Phase 3

Roche
Roche

Columbus, Ohio, United States and 279 other locations

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung C...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Carboplatin

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Columbus, Ohio, United States and 184 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems